Upgrade to SI Premium - Free Trial

Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA) Following Positive Intismeran Data

August 19, 2026 9:34 AM
Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $135.00 price target on Moderna (NASDAQ: MRNA) following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles